Journavx Approval Marks New Era for Pain Relief Medications

On January 30, 2025, the FDA approved Vertex Pharmaceuticals' revolutionary analgesic drug Journavx. Journavx is the first non-opioid, non addictive analgesic that effectively relieves moderate to severe pain, a feat that has never before been accomplished by a non-opioid drug.

Traditionally, when a patient experiences severe pain as a symptom of an ailment or an after-effect of surgery, they are prescribed an opioid based analgesic. Opioids are effective at relieving pain as they activate opioid receptors, which prevent pain signals from being received by the brain. Simultaneously, the activation of opioid receptors prevents neurons from producing GABA, an inhibitory neurotransmitter that is a key regulator of dopamine release. Consequently, the lack of GABA results in a striking increase in dopamine levels. The action of taking opioids then becomes neurologically linked to the pleasurable experience that comes with having high dopamine levels–as the brain becomes wired to repeat the action of taking the opioid to attain that same pleasurable sensation. This is how one ends up with an opioid addiction. With no other alternative analgesic with the same potency as opioids, the risk of addiction to prescribed opioids has become the reality for patients seeking relief from severe pain for decades. Journavx will completely change this. 

There have been multiple studies that have investigated the manner in which Journavx interacts with the nervous system to confirm whether or not the drug poses a risk for addiction. 

A study spearheaded by Jeremiah D. Osteen investigated the mechanism by which Journavx is able to alleviate pain without posing addictive risks. The results of the study led Osteen and his team to conclude that the drug's non-addictive nature is the result of the fact that it exclusively interacts with the peripheral nervous system.  Journavx inhibits voltage-gated sodium channel 1.8 (NaV1.8), a pain-sensing neuron that is selectively expressed in the peripheral nervous system and not present in the central nervous system. The stabilization of the closed state of Nav1.8 prevents sodium flow, which prevents the ability of the pain-sensing neuron to overcome its threshold potential. The inability of the neuron to overcome its threshold potential prevents  the pain signal from being transmitted. Osteen also conducted phase 3 clinical trials on 2447 participants in which a systematic analysis of adverse event data was conducted to assess the efficacy of the drug as an analgesic. It proved to be effective in alleviating moderate to severe pain. 

In comparison with other mainstream pain killers, it is obvious that the brilliance of Journavx lies in the unique way in which it interacts with the body’s nervous system. Although we cannot predict how the industry will utilize the discovery of how this novel drug interacts with a niche mechanism in the nervous system, we can remain assured that it will serve as an inspiration for researchers to continue closely investigating cellular mechanisms in the hopes of finding other niche pathways that can be hacked.